Gyn Cancer Updates: ESMO 2024

CME

Recent Advances in the Treatment of Ovarian, Endometrial, and Cervical Cancer: Gynecologic Cancer Updates From ESMO 2024

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: October 10, 2024

Expiration: April 09, 2025

Alexandra Leary
Alexandra Leary, MD, PhD
Ana Oaknin
Ana Oaknin, MD, PhD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

The results from the phase II PICCOLO trial evaluating single-agent mirvetuximab soravtansine, an antibody–drug conjugate, in patients with heavily pretreated, FRα-positive ovarian cancer showed a remarkable response rate including for which of the following patient populations?